Bone Marrow Stimulation (Microfracture/Drilling)

Long-Term Survival Data (2024-2025)

→ Microfracture pokes tiny holes in bone to cause bleeding. Stem cells from bone marrow form a clot that becomes "fibrocartilage" - scar-like tissue that's not as strong as real cartilage, but can reduce pain. Like patching with duct tape instead of the original material.

2025 Systematic Review: Mid-to-Long Term Outcomes

A 2025 systematic review of 43 studies (2,721 patients, 5-24 year follow-up) found [71]:

• BMS is the most frequently used treatment for small (<1.5 cm²) primary lesions
  → BMS = Bone Marrow Stimulation; primary = first-time lesion (not a recurrence)
• Survival rates (no revision) at latest follow-up: 87.4% to 100%
• Primary lesions: 82% success rate (95% CI: 78-86%)

2025 Five-Year Follow-Up Study

A 2025 study in Indian Journal of Orthopaedics reports 5-year outcomes [72]:

• Short-term efficacy well-established; mid-to-long term outcomes remain ambiguous
• Focus on pain and functional recovery at 5 years

DGOU 2024 Guidelines

→ DGOU = German Society of Orthopedics and Traumatology (respected European guidelines)

• Debridement with BMS supported for lesions <1.0 cm² without bony defect [24]
  → Debridement = surgically cleaning out damaged/dead tissue
• For lesions >1.0 cm², additional scaffold is recommended [24]
  → Scaffold = a supportive framework (like construction scaffolding) that helps new tissue grow
• Consensus: OCLs >1.5 cm² require membrane scaffold augmentation [24]
  → OCL = Osteochondral Lesion; augmentation = adding something to enhance the procedure

Cystic Lesions (2025 Meta-Analysis)

A 2025 meta-analysis found no clinical difference between simple and cystic lesions if cyst depth <5-6mm, medial talus location, and patient <40 years old [26].

→ Cystic lesion = has a fluid-filled hole in the bone; simple = just cartilage damage without a bone cyst

However, for large cystic OLT (>300 mm³), autologous osteochondral transfer showed superior survival vs BMS (p=0.042) [27].

→ Autologous = using tissue from your own body (from another location)

2026 CARTILAGE Meta-Analysis: Lower Repair-Tissue Quality After BMS

A meta-analysis of second-look arthroscopy studies found lower repair-tissue quality after BMS than fixation, osteochondral transplantation, or cartilage implantation [169]:

→ This measures how repair tissue looked during a later arthroscopy. It does not prove that patient-reported outcomes are worse, and it did not directly study a post-allograft lesion.

2026: Immediate Weightbearing After BMS Appears Safe

A matched cohort study found no significant difference in outcomes between immediate and delayed weightbearing after arthroscopic BMS at 12 months [170]. This may simplify post-op protocols.

Long-term Concerns

Fibrocartilaginous repair tissue tends to degenerate over time. Good clinical outcomes at midterm, but radiological outcomes showed repair tissue surface damage [20]. This may be a harbinger for long-term problems [28].

→ Fibrocartilaginous = scar-like cartilage (weaker than original hyaline cartilage); harbinger = warning sign

Added August 3, 2026 — a 2026 Level 1 trial that refused to enroll this lesion, and said why

→ The strongest evidence against marrow stimulation here does not come from a study showing it failed. It comes from a study that would not let him in.

A randomized controlled trial compared a precision micro-drilling technique against conventional microfracture in 56 patients with two-year follow-up [318]. The result itself is modest: better sport scores at three and six months, then “after 12 months, there was no significant difference in clinical outcomes between the two groups.” The technique is not available outside China.

The eligibility criteria are the finding. Enrollment required “the diameter of OLTs smaller than 10 mm, the size of OLTs smaller than 100 mm², and the depth of OLTs smaller than 5 mm,” and excluded “large cystic OLTs… history of surgeries… in the same lower extremity.” This lesion — 15 mm, roughly 150 mm², cystic, revision — fails four of those at once. Enrolled lesions averaged 59–64 mm², under half its size.

And the authors give their reason in the paper: “OLTs larger than 100 mm² or those associated with large cysts (which usually increase lesion depth to larger than 5 mm) have a low success rate with BMS and generally require more aggressive treatments such as autologous osteochondral transplantation or autologous osteoperiosteal transplantation. Therefore, these patients were not included in the present study.” That is a 2026 trial team with an academic stake in a marrow-stimulation device independently restating the 2018 consensus Grade A1 statement recorded on this site — and declining to enroll this phenotype at all.

Added August 3, 2026 — medial and cystic is the worst combination for this operation

Two cohort studies, new to this site, narrow the picture to this exact lesion. A matched comparison of 31 medial against 31 lateral cystic talar lesions found medial lesions did significantly worse after marrow stimulation: less improvement in daily-life and sport scores (P = .034, P < .001), lower repair-tissue scores, and a post-operative cyst rate of 45.2% versus 16.1% (P = .013). On the sport score, only 51.6% of medial patients exceeded the minimum clinically important difference, against 80.6% of lateral [320]. This lesion is medial and cystic.

A companion study of 82 patients identified thresholds beyond which outcomes after marrow stimulation deteriorate: area 90.9 mm², depth 7.56 mm, volume 428 mm³ [321]. At ~150 mm² this lesion is 65% past the area threshold — but read that carefully: the study enrolled only lesions under 100 mm², so the cutoff is extrapolated to him rather than measured on him.

→ Two honest discounts. Both studies are Level III and retrospective, and all three of these findings come from the same institution, which is a real independence problem. They do not prove what would happen to this ankle. What they do is describe what the MASCOT trial's comparator arm is likely to deliver for this specific phenotype — which is a question for the consent conversation, not a reason to avoid the trial.